Development of assays and reagents for monkeypox vaccines
Active Awarded Last action
- Contract number
- 75N93022F00004
- Awardee
-
Battelle Memorial Institute UEI F125YU6SWK59
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,833,162
Award facts
- Contract value 100% obligated
- $3,833,162.00 Current and potential, with all options
- Completion date 96% complete
- Current and potential, with all options
- NAICS code
- 541713 Research and Development in Nanotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Columbus, OH 43201, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $1,278,083 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $632,480 | |
| Supplemental Agreement for work within scope | $393,164 | |
| Supplemental Agreement for work within scope | $484,304 | |
| Original award | $1,045,131 |
About this award
Battelle Memorial Institute, a large nonprofit research and development organization headquartered in Columbus, Ohio, was awarded a delivery order by the National Institute of Allergy and Infectious Diseases (NIAID) on September 1, 2022, to develop assays and reagents for monkeypox vaccines. The contract, valued at $3.83 million and structured as a Cost Plus Fixed Fee arrangement with no set-aside designation, extends through December 31, 2026. This delivery order falls under NIAID's $136.6 million Evaluation and Testing Services for Vaccines and Other Biologics for Infectious Diseases indefinite delivery contract, which provides flexible access to Battelle's vaccine and biologic testing capabilities through September 29, 2035. The work will be performed at Battelle's Columbus, Ohio facility.
The contract supports NIAID's mission to develop medical countermeasures against infectious disease threats by enabling the creation of specialized laboratory tools necessary for vaccine development and evaluation. Battelle brings extensive experience in this domain, having established significant relationships with NIAID and related health agencies through prior work providing pre-clinical evaluation services for antiviral drug candidates, vaccine testing support, and animal model development. The assays and reagents developed under this delivery order will serve as critical components in the vaccine development pipeline, supporting both research and regulatory pathways for monkeypox medical countermeasures during a period of heightened public health concern.
Quick answers
Who was awarded contract 75N93022F00004?
75N93022F00004 was awarded to Battelle Memorial Institute by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2022.
How much is contract 75N93022F00004 worth?
The government has obligated $3,833,162 on 75N93022F00004.
Is contract 75N93022F00004 an order under another contract?
Yes. 75N93022F00004 is a delivery order under 75N93018D00013, an indefinite delivery contract.
Was contract 75N93022F00004 competed?
The extent of competition for 75N93022F00004 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award